Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allium sativum ethyl acetate extract (EAEAS) is a specialized phytochemical preparation derived from garlic, currently under investigation for its potential as an adjuvant therapy in acute myeloid leukemia (AML). Research indicates that EAEAS exerts potent cytotoxic effects on AML blasts by inducing the intrinsic apoptotic pathway. This mechanism involves mitochondrial membrane depolarization, DNA fragmentation, and the activation of executioner caspases 3 and 7. Furthermore, preliminary evidence suggests that the extract may possess selective activity against leukemia stem cell (LSC) subpopulations, which are often resistant to conventional chemotherapy and responsible for disease relapse. Developed primarily in academic research settings, such as the University of Tunis El Manar, EAEAS represents a natural product-based approach to enhancing treatment outcomes in hematological malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allium sativum ethyl acetate extract.